linjc16/ctgov huggingface dataset:
Intubation Success Rate_Rigid Video Stylet Vs Video Laryngoscope

Study Overview
=================
Brief Summary
-----------------
This study compare the intubation success rate between video laryngoscope and rigid video stylet in cervical spine surgery patients. Half of patients will receive endotracheal intubation by video laryngscope, other half of patients will receive endotracheal intubation by rigid video laryngoscope.

Detailed Description
-----------------
Video laryngoscope and lightwand are widely used at endotracheal intubation in cervical spine patients. Video laryngoscope is useful because of identification of anatomic structure around the oral cavity and vocal cord. Rigid video stylet resemble lightwand, but it has a video at the end of stylet. So rigid video stylet is useful at confirmation of vocal cord.

Official Title
-----------------
Comparison of the Initial Intubation Success Rate Between Video Laryngoscope and Rigid Video Stylet in Patients Undergoing Cervical Spine Surgery

Conditions
-----------------
Intubation, Intratracheal

Intervention / Treatment
-----------------
* Device: Rigid video stylet
* Device: Video laryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 80 years old adult patients, ASA class I-III Cervical spine surgery in general anesthesia Exclusion Criteria: Patients who did not agree with the study History of GERD Congenital or acquired lesion like tumor, polyp, trauma, abcess, inflammation, foreign body Surgery of trachea or airway History of radiation around neck area Increased possibility of aspiration Coagulation abnormality

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Optiscope<br>Endotracheal intubation by rigid video stylet, manufactural named Optiscope. | Device: Rigid video stylet<br> <br> * Other names: Optiscope;|
| Active Comparator: McGrath<br>Endotracheal intubation by video laryngoscope, manufactural named McGrath. | Device: Video laryngoscope<br> <br> * Other names: McGrath;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of success rate between two groups |  | immediately | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survey of blood tinged endotracheal tube, bleeding in oral cavity, hoarseness, sore throat |  | Within 24 hours after endotracheal intubation |
Bacterial Contamination in Transrectal Hybrid NOTES Sigmoidectomy

Study Overview
=================
Brief Summary
-----------------
Transrectal Hybrid natural orifice translumenal endoscopic surgery sigmoidectomy has gained popularity. It is an appealing technique as a minilaparotomy in order to retrieve the specimen is avoided. Therefore less postoperative pain and a better cosmetic result are expected. The feasibility of the technique has been demonstrated. Still an open question is the risk of intraperitoneal contamination as in this procedure the colon has to be opened. This is the case for (a) retrieval of the specimen thru the opened rectal stump and (b) for intracorporeal insertion of the anvil of the circular stapler in order to fashion an anastomosis. In this study the bacterial contamination in the rectal stump as well as in the peritoneal cavity is assessed. The results are compared to bacteriological samples taken in a comparison group consisting of conventional laparoscopic assisted sigmoidectomies.

Official Title
-----------------
Bacterial Contamination in Transrectal Hybrid Natural Orifice Translumenal Endoscopic Surgery Sigmoidectomy for Diverticular Disease

Conditions
-----------------
Diverticular Disease

Intervention / Treatment
-----------------
* Procedure: Transrectal sigmoidectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Status post several episodes of diverticulitis Status post contained diverticulitis Exclusion Criteria: not able to give informed consent <18 years of age pregnancy emergency operation acute diverticulitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transrectal sigmoidectomy<br>Patients undergoing transrectal NOTES sigmoidectomy | Procedure: Transrectal sigmoidectomy<br> <br> |
| Laparoscopic-assisted sigmoidectomy<br>Patients undergoing laparoscopic-assisted sigmoidectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peritoneal bacterial contamination | microbacteriological swabs | during surgery | 
| Contamination in the rectal stump after wash-out |  | during surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| septic complications |  | within 30 days after surgery |
Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.

Official Title
-----------------
The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.

Conditions
-----------------
Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: rhEGF(recombinant human Epidermal Growth Factor)
* Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rhEGF(recombinant human Epidermal Growth Factor)<br>BID | Drug: rhEGF(recombinant human Epidermal Growth Factor)<br> <br> |
| Placebo Comparator: placebo<br>BID | Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| At 12 weeks, wound closure rate of diabetic foot ulcers |  | 12 weeks from the start day of treatment (But, the study can be finished before 12 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to reach complete wound closure |  | 12weeks | 
| average size reduction of diabetic ulcer |  | 12 week |
Laparoscopic Vs. Open Prostatectomy Outcomes

Study Overview
=================
Brief Summary
-----------------
This study is aimed at discovering the differences in outcomes, regarding quality of life issues(continence, impotence) of patients who have had either laparoscopic or open surgical technique for prostate cancer.

Detailed Description
-----------------
This study is a post surgical, data collection effort in order to gather definitive, Quality of Life(continence, impotence) information regarding the outcomes of patients who have undergone either Laparoscopic vs. Prostatectomy surgeries for Prostate Cancer. As part of the study, 200 subject's medical records will be retrospectively reviewed and 100 current subjects will be prospectively contacted. The information collected may benefit patients who undergo a prostatectomy

Official Title
-----------------
Laparoscopic Vs. Open Prostatectomy Outcomes

Conditions
-----------------
Prostate Cancer Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have undergone a prostatectomy Exclusion Criteria: none
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The post-surgical questionnaire information collected will be used to determine any benefits to future patients who are to undergo a prostatectomy |  | Post Surgical | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate Cancer Surgery, Laparoscopic surgery for Prostate Cancer, Prostatectomy, Urologic Surgical Procedures
Population Research of Sublingual Microcirculation Data of Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study will enrolled 90 healthy volunteers. The sublingual microcirculation will be examined by sidestreamdark-field videomicroscopy (MicroScan;Microvision Medical, Amsterdam, The Netherlands). Five video sequences (20 s) was obtained from different sublingual sites, and digitally stored the images with code numbers that did not reflect volunteers' information for later offline analysis by automated analysis software (AVA 3.0; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands).

Official Title
-----------------
Population Research of Sublingual Microcirculation Data of Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers aged from 20 to 79 years old BMI ranged from 18.5 to 27 kg/m2 Exclusion Criteria: Systolic blood pressure > 140 mm Hg, diastolic blood pressure > 95 mm Hg, or systolic blood pressure < 90 mm Hg at enrollment Body temperature > 37.5 ℃ or < 35.5 ℃ at enrollment had been diagnose with any one of the following diseases hypertension diabetes mellitus peripheral arterial occlusive disease coronary arterial disease liver cirrhosis chronic kidney disease stroke anemia asthma chronic bronchitis any metabolic diseases any hematologic disease uncured cancer chronic uncontrolled infection other disease may limit daily activities non-native speakers

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Age 20-39<br>Patients aged from 20 to 39 years old. | Other: No intervention<br>* No Intervention<br>|
| Age 40-59<br>Patients aged from 40 to 59 years old. | Other: No intervention<br>* No Intervention<br>|
| Age 60-79<br>Patients aged from 60 to 79 years old. | Other: No intervention<br>* No Intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total small vessel density of sublingual small vessels | Total small vessel density will be measured by Microscan and analyzed by AVA 3.0 software. | Once at enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfused small vessel density of sublingual small vessels | Perfused small vessel density will be measured by Microscan and analyzed by AVA 3.0 software. | Once at enrollment |
Biobehavioral Determinants of Obesity in Black Women

Study Overview
=================
Brief Summary
-----------------
To examine the biobehavioral determinants of obesity in Black as compared with white women.

Detailed Description
-----------------
BACKGROUND: Behavioral medicine surveys consistently find that obesity is a treatment-resistant disease that continues to be a significant health problem and that the incidence of obesity is much higher in Blacks relative to whites in general, and even higher in Black women relative to white women. In fact, an NIH Program Announcement (PA-91-99), stated that Obesity in adults has not declined in the past three decades and Obesity is particularly prevalent in minority populations, especially among minority women. Obesity is an independent risk factor for cardiovascular disease, stroke, and hypertension. Obesity is a complex phenomenon involving behavioral, lifestyle, and complex biobehavioral mechanisms. In 1995, there were no prospective studies that simultaneously evaluated a systematic set of psychosocial variables with energy balance (dietary intake, physical activity, resting metabolic rate) determinants that may account for the increased risk for obesity in African-American versus Euro-American women. DESIGN NARRATIVE: After subjects were recruited, psychosocial and energy balance (dietary intake, physical activity, metabolic rate) baseline measures were related to levels of body fat as measured by DEXA (dual electron X-ray absorptiometry). The role of these variables were evaluated prospectively to adiposity changes in both white and Black women over a 24-month period.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Obesity, Telangiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by the HPV types in the study vaccine, (2) To demonstrate that the vaccine is well-tolerated in women, (3) To evaluate vaccine immune responses in women. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Official Title
-----------------
Proprietary Information - Exploratory (Non-Confirmatory) Trial

Conditions
-----------------
Cervical Cancer, Condylomata Acuminata

Intervention / Treatment
-----------------
* Biological: V502


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, between the ages of 16 and 26 Exclusion Criteria: History of an abnormal PAP test or abnormal cervical biopsy result History of external genital/vaginal warts History of positive HPV test Currently a user of any illegal drugs or an alcohol abuser Are pregnant Currently enrolled in another clinical trial Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent).

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 26 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: V502|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proprietary Information - Exploratory (Non-Confirmatory) Trial |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proprietary Information - Exploratory (Non-Confirmatory) Trial |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, anogenital warts, premalignancy, Human papillomavirus
Characterization of Cancer Tissue Using 3D Biosynthetic Material

Study Overview
=================
Brief Summary
-----------------
Characterization of Cancer Tissue Using 3D Biosynthetic Materials. Using liver biopsy from stage 4 cancer patients, the investigators will evaluate and characterize the metastatic cells.

Detailed Description
-----------------
The investigators' biomaterial lab has developed an in vitro diagnostic system in which a cancer tumor is placed inside a 3D hydrogel. This material has similar properties to the human tissue and can visualize cell migration and proliferation. In this system, the investigators have already characterised human metastatic cells obtained from nude mice tumors. The diagnostic assay is able to evaluate the reduction in cell growth associated with anti-cancer drug therapy. The next step is to test the in vitro diagnostic system using human tissue samples from human patients, and to validate the system as a simple and effective a priori diagnostic tool for characterizing patient tumours.

Official Title
-----------------
Characterization of Cancer Tissue Using 3D Biosynthetic Material

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Procedure: Analyzing biopsy samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: liver tumor Exclusion Criteria: refuse to volunteer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cell growth | biopsy will be placed inside 3D gel, and growth will be measured over 1 week time. | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, diagnosis, biopsy, chemotherapy drugs, tumor
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to detetct Circulating tumor cells(CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) in patients with pulmonary nodules using a novel microfluidic CTC-detection system. Then construct an early diagnostic model for lung cancer.

Detailed Description
-----------------
Patients found pulmonary nodules by CT screening will be enrolled in this study prospectively. CTCs and CAMLs both are cancer specific biomarkers found in the peripheral blood of patients with solid tumors including lung cancer. Through detecting CTCs and CAMLs in healthy volunteers and patients with pulmonary nodules who undergo biopsy, determine the cut-off value of the test. Further analysis of the test specificity and sensitivity, and on this basis construct an early diagnostic model for lung cancer.

Official Title
-----------------
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

Conditions
-----------------
Healthy, Pulmonary Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female or male, 18 years of age or older Pulmonary nodules diagnosed by chest CT or low-dose computed tomography (LDCT) scans Exclusion Criteria: Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Volunteers<br> | |
| Patients With Pulmonary Nodule<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of prevalence of CTCs and CAMLs in patients with pulmonary nodules | The number of CTCs and CAMLs will be detected in the peripheral blood of patients with pulmonary nodules using a novel microfluidic CTC-detection system. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of optimal cut-off values for screening Lung Cancer paitents | The optimal cut-off values will be determined by the ROC analyses. | 6 months |
Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital

Study Overview
=================
Brief Summary
-----------------
study epidemiology of lupus nephritis patients admitted to nephrology unit inward or in outpatient clinic in Assiut Nephrology Unit

Detailed Description
-----------------
this study are: To describe socio-demographic characteristics of lupus nephritis patients in Nephrology Unit of Assiut University hospital ( Old and New cases). To determine the associated risk factors in the study population To describe the clinical, laboratory characteristics, treatment modalities of lupus nephritis patients in Nephrology Unit of Assiut University hospital ( Old and New cases) To Identify outcomes of treatment of these cases within 2 years according to different classes To evaluate the effectiveness of (type of interventions mentioned) among those patients.

Official Title
-----------------
Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital

Conditions
-----------------
Lupus Nephritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients admitted to nephrology unit or visiting the outpatient nephrology clinic,previously or newly diagnosed with lupus nephritis. Exclusion Criteria: incomplete Criteria for diagnosis of systemic lupus or presence of associated renal disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of epidemiology of lupus nephritis patients | Detection of different risk factors such as socioeconomic status and its relation to lupus nephritis To study the outcome of treatment plans in different classes of lupus nephritis | 6 months |